Christopher Hall recognizes a good market opportunity. He wants to be to sneaker lovers what Bill Ackman is to shareholders. » Read More
Traders seem encouraged by the recent bout of Chinese economic data. They may be wrong.
Activist investor Bill Ackman has long had an ax to grind against Herbalife. Now, the battle is the subject of a big-screen documentary.
Herbalife has just issued this response to Bill Ackman and the new movie "Betting on Zero."
In Ted Braun's new documentary, "Betting On Zero," hedge fund titan Bill Ackman doubles down on a surprising adversary: Herbalife. He joins to discuss.
Shares of Valeant Pharmaceuticals fell in after-hours trading on a report that a bond investor may call a default.
Billionaire investors have been on the wrong end of some pretty big recent stock trades. It's a list that even includes Warren Buffett.
Some of the names on the move ahead of the open.
The "Worldwide Exchange" crew discusses the morning's top attention-grabbing headlines, including a piece written in the Wall Street Journal titled, "Jack Lew's Corporate Tax Ambush," and a look at billionaire Bill Ackman's huge losses from bets on Herbalife and Valeant.
Billionaire investor William Ackman faced close questioning on Wednesday when he detailed his hedge fund's biggest-ever quarterly loss.
William Ackman's Pershing Square fund lost 7.1 percent last month, hurt largely by Valeant Pharmaceuticals' roughly 60 percent tumble in March.
According to the "most powerful woman in hedge funds," Leda Braga of Systematica, machines have an edge when betting on stocks going down.
ValueAct, an activist investment firm, paid the price for being a longtime investor in Valeant Pharmaceuticals, says the New York Times.
Discussing ways to bet on hedge fund manager Bill Ackman, with Stephanie Link, TIAA Equities, and the FMHR traders.
U.S. legislators have asked William Ackman's hedge fund for information on Valeant, according to a person familiar with the matter.
A federal jury has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing on patents for hepatitis C drugs.
Valeant announces that CEO Mike Pearson is leaving and that former CFO Howard Schiller refused to quit the board to make room for Bill Ackman.
The situation surrounding Valeant Pharmaceuticals has transformed the company into a "great mystery," CNBC's Jim Cramer says.
Check out the companies making headlines after the bell Thursday: ADBE, SFLY, ARO and more.
Bill Ackman should have listened!
After Valeant took a bite out of Bill Ackman's hedge fund, the billionaire described his firm's standing to CNBC's Scott Wapner.